science
Trial Data: Nipocalimab Reduces IgG by 64% in Myasthenia Gravis Patients Over 120 Weeks
Johnson & Johnson's Imaavy (nipocalimab) showed sustained improvements in generalized myasthenia gravis through 120 weeks, according to seekingalpha.com. The treatment cut IgG levels by 64% and boosted symptom control. Imaavy is a product developed by J&J.
Apr 22, 9:46 AM·1m read1 source
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Com reported. The treatment reduced IgG levels by 64% and improved symptom control in patients with generalized myasthenia gravis, based on trial data. Imaavy (nipocalimab) is a product of J&J. The data indicated consistent benefits over the extended period, with reductions in IgG contributing to the observed improvements.
Com detailed these outcomes in its coverage of the pharmaceutical development.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationLimited · 1 source
